In the SUSTAIN 6 trial, over 3,297 patients with type 2 diabetes with established chronic kidney disease and/or cardiovascular disease underwent randomization to semaglutide or placebo and were followed for 2 years resulting in a 26% risk reduction in the combined endpoint of rate of cardiovascular disease, nonfatal myocardial infarction, or nonfatal stroke [47]
Characteristics of elderly patients initiating sitagliptin or non-DPP-4-inhibitor oral antihyperglycemic agents: analysis of a cross-sectional US claims database
Patients should know plan details because out-of-pocket costs can be high if coverage is denied
Receptor activity profiling assays are a primary use case, including second messenger assays and pathway engagement readouts where concentration accuracy and timing precision are critical
One caveat: These meat sticks don't provide fiber
We don't know the price yet, but let's be realistic